These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20511320)

  • 1. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
    Hamberg P; Verweij J; Sleijfer S
    Oncologist; 2010; 15(6):539-47. PubMed ID: 20511320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.
    Kumar R; Knick VB; Rudolph SK; Johnson JH; Crosby RM; Crouthamel MC; Hopper TM; Miller CG; Harrington LE; Onori JA; Mullin RJ; Gilmer TM; Truesdale AT; Epperly AH; Boloor A; Stafford JA; Luttrell DK; Cheung M
    Mol Cancer Ther; 2007 Jul; 6(7):2012-21. PubMed ID: 17620431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
    Kummar S; Srivastava AK; Navas T; Cecchi F; Lee YH; Bottaro DP; Park SR; Do KT; Jeong W; Johnson BC; Voth AR; Rubinstein L; Wright JJ; Parchment RE; Doroshow JH; Chen AP
    Invest New Drugs; 2021 Dec; 39(6):1577-1586. PubMed ID: 34180036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib in ovarian cancer.
    McLachlan J; Banerjee S
    Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.
    Suttle AB; Ball HA; Molimard M; Hutson TE; Carpenter C; Rajagopalan D; Lin Y; Swann S; Amado R; Pandite L
    Br J Cancer; 2014 Nov; 111(10):1909-16. PubMed ID: 25349968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
    Verweij J; Sleijfer S
    Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib: Clinical development of a potent anti-angiogenic drug.
    Schutz FA; Choueiri TK; Sternberg CN
    Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
    Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
    Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
    Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
    Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pazopanib on tumor microenvironment and liposome delivery.
    Tailor TD; Hanna G; Yarmolenko PS; Dreher MR; Betof AS; Nixon AB; Spasojevic I; Dewhirst MW
    Mol Cancer Ther; 2010 Jun; 9(6):1798-808. PubMed ID: 20515941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.
    Glade Bender JL; Lee A; Reid JM; Baruchel S; Roberts T; Voss SD; Wu B; Ahern CH; Ingle AM; Harris P; Weigel BJ; Blaney SM
    J Clin Oncol; 2013 Aug; 31(24):3034-43. PubMed ID: 23857966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.
    Horita S; Watanabe M; Katagiri M; Nakamura H; Haniuda H; Nakazato T; Kagawa Y
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00545. PubMed ID: 31763044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma.
    Ranieri G; Mammì M; Donato Di Paola E; Russo E; Gallelli L; Citraro R; Gadaleta CD; Marech I; Ammendola M; De Sarro G
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):322-9. PubMed ID: 24041629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib in the treatment of soft tissue sarcoma.
    Schöffski P
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.
    Verheijen RB; Beijnen JH; Schellens JHM; Huitema ADR; Steeghs N
    Clin Pharmacokinet; 2017 Sep; 56(9):987-997. PubMed ID: 28185218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy.
    Sloan B; Scheinfeld NS
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1324-35. PubMed ID: 19037839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.